Skip to content
HowShorted

GeneDx Holdings Corp. Class A short interest in 2025

In 2025, GeneDx Holdings Corp. Class A's disclosed short interest ran from 7.78% of shares outstanding on 15 Jan 2025 to 10.63% on 31 Dec 2025, a change of +2.85 percentage points. The year's high was 13.13% on 13 Jun 2025 and its low 7.78% on 15 Jan 2025, averaging 11.29% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.59 days on 15 Dec 2025. Full history: GeneDx Holdings Corp. Class A.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for GeneDx Holdings Corp. Class A in 2025

2025 in figures

Start of year
7.78% (15 Jan 2025)
End of year
10.63% (31 Dec 2025)
Change
+2.85 pp
High
13.13% (13 Jun 2025)
Low
7.78% (15 Jan 2025)
Average
11.29%
Highest days to cover
8.59 (15 Dec 2025)
SEC filings marked
9

Every report in 2025

GeneDx Holdings Corp. Class A short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20257.78%1.96results (8-K)
31 Jan 20257.79%3.25
14 Feb 20259.81%1.79
28 Feb 20259.00%1.56results (8-K), 10-K filed
14 Mar 20258.88%2.99
31 Mar 20259.84%4.61
15 Apr 202511.59%3.68
30 Apr 202512.52%2.2510-Q filed, results (8-K)
15 May 202512.18%1.91
30 May 202512.74%4.27
13 Jun 202513.13%5.54
30 Jun 202512.88%3.04
15 Jul 202512.20%4.77
31 Jul 202512.67%3.2410-Q filed, results (8-K)
15 Aug 202513.13%5.16
29 Aug 202512.65%5.10
15 Sep 202512.57%8.06
30 Sep 20259.82%5.72
15 Oct 202510.44%6.02
31 Oct 202512.12%5.3610-Q filed, results (8-K)
14 Nov 202512.49%6.77
28 Nov 202512.43%7.26
15 Dec 202511.71%8.59
31 Dec 202510.63%7.94

See also: GeneDx Holdings Corp. Class A's full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.